G-CSF in the Treatment of Toxic Epidermal Necrolysis

Summary

NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial. Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.

Timeline

Start

2016-07

Primary completion

2023-03-07

Completion

2023-03-07

Drugs

Indications